Touyun Biotech Group Balance Sheet Health
Financial Health criteria checks 0/6
Touyun Biotech Group has a total shareholder equity of HK$-25.6M and total debt of HK$369.2M, which brings its debt-to-equity ratio to -1443.6%. Its total assets and total liabilities are HK$571.8M and HK$597.4M respectively.
Key information
-1,443.6%
Debt to equity ratio
HK$369.19m
Debt
Interest coverage ratio | n/a |
Cash | HK$13.76m |
Equity | -HK$25.57m |
Total liabilities | HK$597.42m |
Total assets | HK$571.84m |
Recent financial health updates
Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?
Apr 08Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt
Sep 19Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Sep 13Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt
May 18Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Dec 24Recent updates
Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%
Sep 15Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jul 17Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%
Apr 22Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?
Apr 08What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You
Feb 07Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding
Dec 18Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt
Sep 19Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)
Jul 28Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Sep 13Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt
May 18Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt
Dec 24Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?
Mar 12If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns
Jan 15The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares
Jan 15How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?
Dec 11Financial Position Analysis
Short Term Liabilities: 1332 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 1332 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 1332 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 1332's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1332 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 1332 has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 12:25 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Touyun Biotech Group Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|